No Data
No Data
Replimune Begins RP2 Clinical Trials With First Patients Enrolled In Metastatic Uveal Melanoma And Hepatocellular Carcinoma
Express News | Replimune Group Inc - Primary Endpoints of Rp2-202 Study Are Overall Survival and Progression Free Survival
Replimune to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Replimune Management to Meet With Jefferies
Analysts Are Bullish on These Healthcare Stocks: Inovio Pharmaceuticals (INO), Replimune Group (REPL)
Jefferies Maintains Buy on Replimune Group, Raises Price Target to $19
No Data